Stock Sale By Pfizer’s Bourla Exemplifies Possible Need For Reform, US Senators Tell SEC
Executive Summary
Sens. Brown, Warren and Van Hollen portray biopharma as the poster child of potential corporate abuses of so-called 10b5-1 plans, which are designed to allow executives to sell stock while avoiding insider trading.
You may also be interested in...
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.